CONFLICT OF INTEREST STATEMENT
ONCOLOGY
AC received institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Natera, and Fibrogen; advisory board or speaker fees from Amgen, Merck Serono, and Roche. AHS, JW, MD, JPM, GK, and ASR have no conflicts of interest to disclose. CB received consulting or advisory fees from Roche, Sanofi, MSD, and Bayer. CDL received grants or has contracts with Taiho, Roche, AstraZeneca, Servier, and AACR. HK received grants or has contracts with Chugai Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical CO. Ltd., Taiho Pharmaceutical, and Eisai Co. Ltd; consulting fees from Daiichi Sankyo; payment or honoraria from Bristol Myers Squibb, Eli Lilly Japan K.K, Ono Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd, GlaxoSmithKline K.K, Bayer Yakuhin Ltd, MSD K.K., Chugai Pharmaceutical Co. Ltd, Merck Biopharma Co., Ltd, Yakult Pharmaceutical Industry, Taiho Pharmaceutical, and Otsuka Pharmaceutical Co., Ltd. KM declares institutional research funding from Astellas, Amgen, Solasia Pharma, Taiho, Merck Serono, Daiichi Sankyo, Parexel International, Pfizer, MSD, ONO Pharmaceutical, Sanofi, and Eisai; advisory board or speaker fees from AstraZeneca, ONO Pharmaceutical, Amgen, Chugai, Takeda, Taiho, Sanofi, Bristol Myers Squibb, Eli Lilly, and Bayer. LS declares consulting or advisory role with MSD, Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo, Roche, Mingji Biopharmaceutical, Harbour BioMed, and Merck; speakers' bureau with Hutchison Whampoa and MSD; research funding from Nanjing Yaojieankang Biotechnology (Inst), Baiji Shenzhou (Beijing) Biotechnology Co. Ltd (Inst), Beijing Xiantong Biomedical Technology Co. Ltd (Inst), QiLu Pharmaceutical (Inst), and Zaiding Pharmaceutical (Inst). MC declares consulting and advisory role or speaker with Roche, Eisai, MSD, and Bayer; safety monitoring board with Nerviano. NG, ZZ, and RJP are employed by and have stock ownership in BeiGene. YJB declares institutional funding from Genentech/Roche, Merck Serano, Astellas, MSD, Daiichi Sankyo, and Amgen; consulting fees from MSD, Daiichi Sankyo, Samyang Biopharm, Hanmi, Merck Serano, Astellas, Alexo Oncology, Daewoong, and Amgen.